On Monday, AstraZeneca Plc AZN shared detailed results from the HICKORY Phase 3 trial of efzimfotase alfa (ALXN1850) for ...

Astrazeneca (NYSE:AZN) presented Phase III data for efzimfotase alfa, an investigational enzyme replacement therapy for ...

Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in ...

Citi has maintained its 'buy' rating on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) with a target price of £186, arguing that ...

The investment is expected to increase the pharma giant's workforce in Massachusetts to 3,000 employees within a few years.

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical ...

Summit shares surged in after-hours trading following the news of AstraZeneca’s investment, as the two companies plan to ramp up their collaboration on developing cancer treatments.

Oct 5 (Reuters) - AstraZeneca said on Monday it would spend more than $1 billion in Massachusetts as part of its broader $50 ...

Justin Dynlacht thought his employer and health insurer didn’t provide adequate coverage for Crohn’s disease, but took his ...

AstraZeneca is investing $2 billion in Summit Therapeutics to accelerate the development of PD-1xVEGF bispecific ivonescimab in combination with antibody-drug conjugates (ADCs). The newly minted ...